Pancreatic cancer: Biomarker landscape

Emmanuel Kwaku Ofori; Nathaniel Ebo Aidoo

doi:10.1016/B978-0-443-33902-8.00002-X

Pancreatic cancer: Biomarker landscape

Emmanuel Kwaku Ofori, Nathaniel Ebo Aidoo

Department of Chemical Pathology

MDS-Lancet Laboratories Ghana Limited

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

Abstract

Pancreatic cancer (PC) remains a difficult sickness to detect and treat since it is typically discovered at an advanced stage. In recent years, there has been a significant increase in interest in finding biomarkers for early PC identification. The goal is to improve patient outcomes by responding promptly. Proteins, microRNAs (miRNAs), circulating tumor cells (CTCs), exosomes, and long noncoding RNAs (lncRNAs) have all been investigated in various body fluids, such as blood, urine, saliva, and stool to identify biomarkers. Serum CA 19-9, a conventional biomarker, continues to be widely utilized despite its inherent constraints. Despite the difficulties, research into biomarkers for PC detection is essential to improving early diagnosis and, ultimately, patient outcomes.

Original language	English
Title of host publication	Biomarker Landscape in Cancer Research
Publisher	Elsevier
Pages	25-40
Number of pages	16
ISBN (Electronic)	9780443339028
ISBN (Print)	9780443339035
DOIs	https://doi.org/10.1016/B978-0-443-33902-8.00002-X
Publication status	Published - 1 Jan 2025

Keywords

Biomarkers
Circulating tumor cells
Inflammation
MicroRNA
Pancreatic cancer
Serological
Surgery
Urine proteins

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/B978-0-443-33902-8.00002-X

Cite this

@inbook{435e1ce703574a0f8059ac3f9508a307,

title = "Pancreatic cancer: Biomarker landscape",

abstract = "Pancreatic cancer (PC) remains a difficult sickness to detect and treat since it is typically discovered at an advanced stage. In recent years, there has been a significant increase in interest in finding biomarkers for early PC identification. The goal is to improve patient outcomes by responding promptly. Proteins, microRNAs (miRNAs), circulating tumor cells (CTCs), exosomes, and long noncoding RNAs (lncRNAs) have all been investigated in various body fluids, such as blood, urine, saliva, and stool to identify biomarkers. Serum CA 19-9, a conventional biomarker, continues to be widely utilized despite its inherent constraints. Despite the difficulties, research into biomarkers for PC detection is essential to improving early diagnosis and, ultimately, patient outcomes.",

keywords = "Biomarkers, Circulating tumor cells, Inflammation, MicroRNA, Pancreatic cancer, Serological, Surgery, Urine proteins",

author = "Ofori, \{Emmanuel Kwaku\} and Aidoo, \{Nathaniel Ebo\}",

year = "2025",

month = jan,

day = "1",

doi = "10.1016/B978-0-443-33902-8.00002-X",

language = "English",

isbn = "9780443339035",

pages = "25--40",

booktitle = "Biomarker Landscape in Cancer Research",

publisher = "Elsevier",

}

TY - CHAP

T1 - Pancreatic cancer

T2 - Biomarker landscape

AU - Ofori, Emmanuel Kwaku

AU - Aidoo, Nathaniel Ebo

PY - 2025/1/1

Y1 - 2025/1/1

N2 - Pancreatic cancer (PC) remains a difficult sickness to detect and treat since it is typically discovered at an advanced stage. In recent years, there has been a significant increase in interest in finding biomarkers for early PC identification. The goal is to improve patient outcomes by responding promptly. Proteins, microRNAs (miRNAs), circulating tumor cells (CTCs), exosomes, and long noncoding RNAs (lncRNAs) have all been investigated in various body fluids, such as blood, urine, saliva, and stool to identify biomarkers. Serum CA 19-9, a conventional biomarker, continues to be widely utilized despite its inherent constraints. Despite the difficulties, research into biomarkers for PC detection is essential to improving early diagnosis and, ultimately, patient outcomes.

AB - Pancreatic cancer (PC) remains a difficult sickness to detect and treat since it is typically discovered at an advanced stage. In recent years, there has been a significant increase in interest in finding biomarkers for early PC identification. The goal is to improve patient outcomes by responding promptly. Proteins, microRNAs (miRNAs), circulating tumor cells (CTCs), exosomes, and long noncoding RNAs (lncRNAs) have all been investigated in various body fluids, such as blood, urine, saliva, and stool to identify biomarkers. Serum CA 19-9, a conventional biomarker, continues to be widely utilized despite its inherent constraints. Despite the difficulties, research into biomarkers for PC detection is essential to improving early diagnosis and, ultimately, patient outcomes.

KW - Biomarkers

KW - Circulating tumor cells

KW - Inflammation

KW - MicroRNA

KW - Pancreatic cancer

KW - Serological

KW - Surgery

KW - Urine proteins

UR - https://www.scopus.com/pages/publications/105011240319

U2 - 10.1016/B978-0-443-33902-8.00002-X

DO - 10.1016/B978-0-443-33902-8.00002-X

M3 - Chapter

AN - SCOPUS:105011240319

SN - 9780443339035

SP - 25

EP - 40

BT - Biomarker Landscape in Cancer Research

PB - Elsevier

ER -

Pancreatic cancer: Biomarker landscape

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this